A Phase 3 interventional study of Fondaparinux sodium and GSK576428 in Venous Thromboembolism, sponsored by GlaxoSmithKline. Completed at 18 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2009-07-10.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
This study is phase 3 study for prevention of VTE in patients with abdominal surgery.
818 studies on the registry are indexed under Thromboembolism; 98 are open to participants now.
This study's enrollment of 127 is below the median of 196 across 436 interventional studies indexed under Thromboembolism.
Browse Thromboembolism studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
Also known as: Fondaparinux sodium
Incidence of Venous thromboembolism and Major bleeding
Time frame: Throughout entire study
Incidence of Pulmonary embolism Incidence of Deep vein thrombosis Incidence of symptomatic Venous thromboembolism
Time frame: Throughout entire study
This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline